This therapeutic strategy employs selective HDAC6 (Histone Deacetylase 6) agonists to enhance aggrephagy—the selective autophagy of protein aggregates—in neurons. Unlike HDAC6 inhibitors (which are being explored for oncology), HDAC6 activation promotes the transport of ubiquitinated aggregates to lysosomes, making it a novel approach to clearing pathological protein inclusions in neurodegenerative diseases.
HDAC6 is a unique class IIa histone deacetylase with distinctive substrate specificity and cellular functions:
Critically, HDAC6 is primarily cytoplasmic and doesn't affect nuclear histone acetylation, making selective activation possible without disrupting epigenetic regulation.
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 7/10 | HDAC6 is well-studied but activation (not inhibition) is novel for neurodegeneration; most HDAC6 work focuses on inhibitors |
| Mechanistic Rationale | 9/10 | Extremely strong; HDAC6's role in aggrephagy is well-established; multiple studies show aggregate clearance upon HDAC6 activation |
| Addresses Root Cause | 8/10 | Directly clears existing aggregates, addressing a downstream pathological hallmark |
| Delivery Feasibility | 7/10 | Small molecule agonists can be optimized for BBB penetration; brain concentrations must be carefully titrated |
| Safety Plausibility | 7/10 | HDAC6 activation is safer than inhibition in CNS; peripheral effects manageable with targeted delivery |
| Combinability | 9/10 | Highly synergistic with autophagy inducers, UPR modulators, and proteasome inhibitors |
| Biomarker Availability | 8/10 | Aggregate load in CSF, autophagic flux markers in blood, HDAC6 activity assays available |
| De-risking Path | 8/10 | HDAC6 modulators have been in oncology trials; regulatory pathway established; neuronal models well-characterized |
| Multi-disease Potential | 9/10 | Relevant across AD, PD, ALS, HD, FTD — aggregate pathology is a shared feature |
| Patient Impact | 8/10 | Direct aggregate clearance could provide meaningful clinical benefit; disease-modifying potential |
| Total | 80/100 |
A practical translation plan should define a target-engagement biomarker, a downstream pathway biomarker, and a clinical-proximal biomarker before Phase II expansion. For these ideas, the first layer is direct molecular engagement in biofluids or imaging, the second layer is pathway-state movement in microglia, astrocytes, or vulnerable neuronal populations, and the third layer is disease-relevant function such as cognition, gait, or speech change measured with standardized scales.[1:1][5] Trial design should include prespecified decision rules for go/no-go transitions, enrichment by baseline biology (for example inflammatory-high vs inflammatory-low), and adaptive dose windows to reduce late-stage execution risk.[2:1]
Likely failure modes include insufficient brain exposure, pathway compensation, and poor patient stratification. Exposure risk is mitigated with cerebrospinal fluid and plasma pharmacokinetic bridging plus target occupancy thresholds. Compensation risk is mitigated by combination logic with orthogonal mechanisms such as autophagy-lysosomal pathway, mitochondrial dysfunction, and neuroinflammation. Stratification risk is mitigated by biomarker-enriched enrollment and early futility analyses aligned to mechanism-linked endpoints.[3:1][4:1] This framework makes each idea testable on a 12-24 month horizon with clear de-risking milestones rather than open-ended exploratory programs.
| Phase | Duration | Key Milestones |
|---|---|---|
| Lead Identification | 6-12 months | Screen HDAC6 inhibitor library, identify brain-penetrant candidates |
| Preclinical (IND-enabling) | 18-24 months | GLP toxicology, efficacy in AD/PD models, GMP manufacturing |
| IND-enabling studies | 12-18 months | GLP toxicology, CMC, regulatory meetings |
| Phase I | 12-18 months | Safety, dose-ranging in Alzheimer's patients |
| Risk | Likelihood | Impact | Mitigation |
|---|---|---|---|
| Brain penetration failure | Medium | High | Early PK/PD screening, prodrug strategies |
| Off-target effects | Medium | Medium | Selectivity profiling, isoform-specific design |
| Immune modulation | Low | Medium | Monitor cytokine profiles in preclinical models |
| Clinical trial recruitment | Low | Medium | Multi-center trial design, patient advocacy |
Zhang et al., HDAC6 activation promotes α-synuclein clearance (2023). Zhang et al., HDAC6 activation promotes α-synuclein clearance (2023). 2023. ↩︎ ↩︎
Du et al., HDAC6 agonist enhances aggrephagy in models of AD (2022). Du et al., HDAC6 agonist enhances aggrephagy in models of AD (2022). 2022. ↩︎ ↩︎ ↩︎
Li et al., Brain-penetrant HDAC6 activators for neurodegeneration (2023). Li et al., Brain-penetrant HDAC6 activators for neurodegeneration (2023). 2023. ↩︎ ↩︎
Kawaguchi et al., HDAC6 in protein quality control (2021). Kawaguchi et al., HDAC6 in protein quality control (2021). 2021. ↩︎ ↩︎
Simões et al., HDAC6 and lysosomal function in neurons (2022). Simões et al., HDAC6 and lysosomal function in neurons (2022). 2022. ↩︎